Old Web
English
Sign In
Acemap
>
authorDetail
>
Naoya Kameyama
Naoya Kameyama
Kyowa Hakko Kirin Co., Ltd.
Ovarian cancer
Immunology
Epitope
Antibody
Cytotoxicity
3
Papers
2
Citations
0
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Potent Therapeutic Activity Against Peritoneal Dissemination and Malignant Ascites by the Novel Anti-Folate Receptor Alpha Antibody KHK2805
2017
Translational Oncology
Munetoshi Ando
Keiko Nagata
Kaito Nihira
Yui Suzuki
Yutaka Kanda
Maiko Adachi
Tsuguo Kubota
Naoya Kameyama
Mariko Nakano
Hiroshi Ando
Kazuya Yamano
Toshihiko Ishii
Ryuichiro Nakai
Kazuyasu Nakamura
Show All
Source
Cite
Save
Citations (2)
Abstract C123: A novel anti-FOLR1 antibody developed with AccretaMab® technology, KHK2805, exhibits markedly high ADCC/CDC activity and a tolerable safety profile in preclinical models
2015
Molecular Cancer Therapeutics
Munetoshi Ando
Keiko Nagata
Hiroshi Ando
Mariko Nakano
Naoya Kameyama
Tsuguo Kubota
Maiko Adachi
Yui Suzuki
Kazuyasu Nakamura
Toshihiko Ishii
Ryuichiro Nakai
Takeshi Takahashi
Show All
Source
Cite
Save
Citations (0)
Anticorps anti-folr1
2013
Munetoshi Ando
syuu minoru andou
Hiroshi Ando
hirosi andou
Mariko Nakano
mari ko nakano
Naoya Kameyama
naoya kameyama
Tsuguo Kubota
rei otto kubota
Show All
Source
Cite
Save
Citations (0)
1